# A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

> **NCT04231747** · PHASE1 · COMPLETED · sponsor: **Juno Therapeutics, a Subsidiary of Celgene** · enrollment: 24 (actual)

## Conditions studied

- Lymphoma Non-Hodgkin
- Agressive Lymphoma
- Diffuse-large B-cell Lymphoma (DLBCL)

## Interventions

- **BIOLOGICAL:** CC-97540

## Key facts

- **NCT ID:** NCT04231747
- **Lead sponsor:** Juno Therapeutics, a Subsidiary of Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-21
- **Primary completion:** 2024-02-01
- **Final completion:** 2024-02-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04231747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04231747, "A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04231747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*